| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0889-8553(05)70049-2 |
| P8608 | Fatcat ID | release_u56txkc4onbbhjtulmtyxeyexi |
| P698 | PubMed publication ID | 10198784 |
| P2093 | author name string | Salen G | |
| Batta AK | |||
| P2860 | cites work | Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis | Q24542418 |
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Metabolism of ursocholic acid in humans: conversion of ursocholic acid to deoxycholic acid | Q28319288 | ||
| Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration | Q28335885 | ||
| Byler Disease | Q29014497 | ||
| Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis | Q34198085 | ||
| Evolution of liver transplantation | Q34275840 | ||
| Ursocholic acid: bile acid and bile lipid dose response and clinical studies in patients with gall stones | Q34391377 | ||
| Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis | Q34392767 | ||
| The epidemiology of primary biliary cirrhosis: a survey of mortality in England and Wales | Q34476962 | ||
| Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology | Q34494124 | ||
| Medical approaches to primary sclerosing cholangitis | Q37755875 | ||
| Bile acids, liver injury, and liver disease | Q39956246 | ||
| Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis | Q40573407 | ||
| Successful treatment of Caroli's disease by hepatic resection. Report of six patients | Q40822746 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease | Q41114391 | ||
| Primary biliary cirrhosis, dark adaptometry, electro-oculography, and vitamin A state | Q41785900 | ||
| Liver disease and bile duct abnormalities in adults with cystic fibrosis | Q42190852 | ||
| Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. | Q42199158 | ||
| Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis | Q43214926 | ||
| Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis | Q43551362 | ||
| Randomized trial of chlorambucil for primary biliary cirrhosis. | Q44093311 | ||
| Deficient interleukin-2 responsiveness of T lymphocytes from patients with primary biliary cirrhosis | Q44257539 | ||
| Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease | Q44969230 | ||
| Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. | Q45089631 | ||
| Hepatic injury induced by bile salts: correlation between biochemical and morphological events | Q46245057 | ||
| Surgical management of Caroli's disease involving both lobes of the liver | Q49262976 | ||
| Primary sclerosing cholangitis. A study of forty-two cases | Q50180408 | ||
| Liver transplantation for primary sclerosing cholangitis versus primary biliary cirrhosis: a comparison of complications and outcome | Q50188783 | ||
| Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. | Q50553464 | ||
| Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. | Q50878460 | ||
| Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. | Q51604167 | ||
| Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. | Q54072767 | ||
| Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. | Q54108650 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. | Q64974270 | ||
| A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results | Q67590480 | ||
| Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial | Q68019501 | ||
| Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease | Q68079285 | ||
| The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is fifty percent of total serum bile acids | Q68111181 | ||
| Immunomodulatory effects of ursodeoxycholic acid on immune responses | Q68225187 | ||
| Orthotopic liver transplantation for Byler disease | Q68599276 | ||
| Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid | Q68925952 | ||
| Bile acid metabolism in cirrhotic liver tissue--altered synthesis and impaired hepatic secretion | Q69443241 | ||
| Efficacy of liver transplantation in patients with primary biliary cirrhosis | Q69507347 | ||
| Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis. Clinical and histologic follow-up studies | Q69520423 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response | Q70021003 | ||
| Enhanced autoreactivity of T-lymphocytes in primary sclerosing cholangitis | Q70038065 | ||
| Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis | Q70043288 | ||
| Bile acid profiles in siblings with progressive intrahepatic cholestasis: absence of biliary chenodeoxycholate | Q70075317 | ||
| Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones | Q70260265 | ||
| Current concepts. Primary sclerosing cholangitis | Q70327279 | ||
| Caroli's disease | Q70329253 | ||
| Byler's disease: fatal intrahepatic cholestasis | Q70430072 | ||
| The identification of urinary bile alcohols by gas chromatography-mass spectrometry in patients with liver disease and in healthy individuals | Q70441074 | ||
| Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial | Q70542319 | ||
| Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy | Q70670255 | ||
| Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis | Q70680436 | ||
| Primary biliary cirrhosis: an epidemiological study | Q71354203 | ||
| Urinary excretion of bile alcohols in normal children and patients with alpha 1-antitrypsin deficiency during development of liver disease | Q71634280 | ||
| Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (Byler disease) | Q72194324 | ||
| Ursodeoxycholic acid therapy in primary biliary cirrhosis | Q72210615 | ||
| Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone | Q72227193 | ||
| Ursodeoxycholic acid treatment of primary hepatolithiasis in Caroli's syndrome | Q72227308 | ||
| Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period | Q72503309 | ||
| Primary sclerosing cholangitis | Q72596376 | ||
| A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency | Q72689608 | ||
| Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC | Q72789964 | ||
| NIH conference: Primary biliary cirrhosis: a model autoimmune disease | Q72796266 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 173-193 | |
| P577 | publication date | 1999-03-01 | |
| P1433 | published in | Gastroenterology Clinics of North America | Q15756082 |
| P1476 | title | Bile acid abnormalities in cholestatic liver diseases | |
| P478 | volume | 28 |
| Q37208510 | A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis |
| Q44552108 | Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity |
| Q40677743 | Effects of bile acids on biliary epithelial cells: proliferation, cytotoxicity, and cytokine secretion |
| Q44124000 | Plasma deoxycholic acid concentration is elevated in postmenopausal women with newly diagnosed breast cancer. |
Search more.